雷迪米基巴特治疗中度至重度,不受控制的喘:一个2B期随机试验
Edward Kerwin1, Ting Yang2, Nan Su3
1Clinical Research Institute, Allergy and Asthma Center of Southern Oregon, Medford, Oregon, United States.
American journal of respiratory and critical care medicine
|February 25, 2025
概括
在24周内,拉德米基巴特显著改善了成年中度至重度喘患者的肺功能和喘控制. 这种针对IL-4Rα的抗体表现出快速,持续的益处,并具有良好的安全性.
科学领域:
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
- 临床试验 临床试验
背景情况:
- 拉德米基巴特 (前CBP-201) 是一种针对IL-4受体α (IL-4Rα) 的抗体.
- 喘是一种慢性呼吸道疾病,其特点是气道炎症和高反应性.
研究的目的:
- 评估拉德米基巴特在患有中度至重度持久性,不受控制的喘的成年人中的疗效和安全性.
- 在24周的时间内评估拉德米基巴特对肺功能和喘控制的影响.
主要方法:
- 全球2b期临床试验 (NCT04773678) 随机选择了322名患者.
- 参与者接受皮下拉德米基巴特 (150毫克或300毫克每隔一周加载剂量) 或安慰剂24周.
- 主要终点是第12周第一秒 (FEV1) 预支气管扩展剂强迫呼气体积的变化.
主要成果:
- 拉德米基巴特在第12周显著改善FEV1 (150毫克:+140毫升,300毫克:+189毫升与安慰剂相比).
- 在FEV1的改善是快速的,持续到24周,最明显的是在血中高血红蛋白基线的患者.
- 观察到喘恶化减少 (拉德米基巴特组7.5%,9.3%,安慰剂组16.7%),喘控制问卷得分改善.
- 治疗出现的不良事件与安慰剂相似,没有发现eosinophilia.
结论:
- 拉德米基巴特在中度至重度喘患者中显示出肺功能和喘控制的快速和持续改善.
- 在24周的研究期间,抗体被耐受性良好.
- 这些发现支持rademikibart作为对失控喘的潜在治疗选择.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
226
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
226
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
226
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
226
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
212
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
212
01:23Inhaled Medications
218
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
218
01:26Asthma-II: Pathophysiology and Classification
2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K